title: Novel management of the microphthalmic orbit in a patient with PHACE syndrome.
abstract: A full-term female infant with severe unilateral microphthalmos and ipsilateral orbital hemangioma in the setting of PHACE syndrome was successfully managed with oral propranolol therapy and subsequent orbital conformer placement. After 3 months of systemic propranolol therapy, the orbital hemangioma had shown significant regression without systemic or local complications. The authors believe this to be the first reported use of systemic propranolol therapy in the management of a hemangioma within a microphthalmic orbit of a patient with PHACE syndrome.
authors.affiliation: University of Illinois Eye and Ear Infirmary, Department of Ophthalmology and Visual Sciences, Chicago, Illinois 60612, USA.
authors.forename: Roshni
authors.initials: R
authors.lastname: Vasaiwala
authors.forename: Kiran
authors.initials: K
authors.lastname: Sajja
authors.forename: Pete
authors.initials: P
authors.lastname: Setabutr
mesh_terms: D000284:Administration, Oral; D001017:Aortic Coarctation / Q000175:diagnosis / Q000628:therapy*; D005124:Eye Abnormalities / Q000175:diagnosis / Q000628:therapy*; D005153:Facial Neoplasms / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006391:Hemangioma / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007223:Infant; D008279:Magnetic Resonance Imaging; D008850:Microphthalmos / Q000175:diagnosis / Q000628:therapy*; D020752:Neurocutaneous Syndromes / Q000175:diagnosis / Q000628:therapy*; D009915:Orbit / Q000002:abnormalities*; D009918:Orbital Neoplasms / Q000188:drug therapy / Q000473:pathology; D011433:Propranolol / Q000627:therapeutic use*; D015626:Tissue Expansion / Q000379:methods*; D015625:Tissue Expansion Devices
chemical_list: D011433:Propranolol